{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:03:24Z","timestamp":1789506204277,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["CRG\/2022\/008672"],"award-info":[{"award-number":["CRG\/2022\/008672"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11010-025-05302-2","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:03:12Z","timestamp":1747911792000},"page":"5157-5172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["YTHDC1 orchestrates oncogenic splicing via the CLK1-SRSF1 splicing machinery to regulate castration-resistant prostate cancer progression"],"prefix":"10.1007","volume":"480","author":[{"given":"Parth","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devesh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B Vishal","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Suseela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthil J.","family":"Rajappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Subramanyeshwar","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"5302_CR1","first-page":"609","volume":"4","author":"D Maillet","year":"2021","unstructured":"Maillet D, Allioli N, Peron J, Plesa A, Decaussin-Petrucci M, Tartas S, Ruffion A, Crouzet S, Rimokh R, Gillet P-G (2021) Improved androgen receptor splice variant 7 detection using a highly sensitive assay to predict resistance to abiraterone or enzalutamide in metastatic prostate cancer patients, European Urology. Oncology 4:609\u2013617","journal-title":"Oncology"},{"key":"5302_CR2","first-page":"271","volume":"7","author":"R Narayanan","year":"2020","unstructured":"Narayanan R (2020) Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer, Asian. J Urol 7:271\u2013283","journal-title":"J Urol"},{"key":"5302_CR3","doi-asserted-by":"publisher","first-page":"7654","DOI":"10.1038\/srep07654","volume":"5","author":"Y Qu","year":"2015","unstructured":"Qu Y, Dai B, Ye D, Kong Y, Chang K, Jia Z, Yang X, Zhang H, Zhu Y, Shi G (2015) Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer. Sci Rep 5:7654","journal-title":"Sci Rep"},{"key":"5302_CR4","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.18632\/oncotarget.1802","volume":"5","author":"B Cao","year":"2014","unstructured":"Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O (2014) Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5:1646","journal-title":"Oncotarget"},{"key":"5302_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1172\/JCI122819","volume":"129","author":"A Sharp","year":"2019","unstructured":"Sharp A, Coleman I, Yuan W, Sprenger C, Dolling D, Rodrigues DN, Russo JW, Figueiredo I, Bertan C, Seed G (2019) Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. J Clin Investig 129:192\u2013208","journal-title":"J Clin Investig"},{"key":"5302_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/modpathol.2017.74","volume":"31","author":"H Li","year":"2018","unstructured":"Li H, Wang Z, Xiao W, Yan L, Guan W, Hu Z, Wu L, Huang Q, Wang J, Xu H (2018) Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients. Mod Pathol 31:198\u2013208","journal-title":"Mod Pathol"},{"key":"5302_CR7","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41388-021-01640-9","volume":"40","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES (2021) Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene 40:2148\u20132149","journal-title":"Oncogene"},{"key":"5302_CR8","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO.18.01731","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ (2019) Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. JCO 37:1120\u20131129. https:\/\/doi.org\/10.1200\/JCO.18.01731","journal-title":"JCO"},{"key":"5302_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clgc.2019.09.015","volume":"18","author":"T Zhang","year":"2020","unstructured":"Zhang T, Karsh LI, Nissenblatt MJ, Canfield SE (2020) Androgen receptor splice variant, AR-V7, as a biomarker of resistance to androgen axis-targeted therapies in advanced prostate cancer. Clin Genitourin Cancer 18:1\u201310","journal-title":"Clin Genitourin Cancer"},{"key":"5302_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/14728222.2018.1439016","volume":"22","author":"T Uo","year":"2018","unstructured":"Uo T, Plymate SR, Sprenger CC (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201\u2013216. https:\/\/doi.org\/10.1080\/14728222.2018.1439016","journal-title":"Expert Opin Ther Targets"},{"key":"5302_CR11","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1093\/hmg\/ddaa089","volume":"29","author":"KT Tietz","year":"2020","unstructured":"Tietz KT, Dehm SM (2020) Androgen receptor variants: RNA-based mechanisms and therapeutic targets. Hum Mol Genet 29:R19\u2013R26","journal-title":"Hum Mol Genet"},{"key":"5302_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2025.102003","volume":"42","author":"R Raut","year":"2025","unstructured":"Raut R, Srivastava D, Nayak V, Saini T, Gupta P, Chakraborty AK, Choudhury C, Bais MV, Mishra P, Misra A (2025) Clinical data investigation identifies MARK3 as an oncogenic driver in castration-resistant prostate cancer. Biochem Biophys Rep 42:102003. https:\/\/doi.org\/10.1016\/j.bbrep.2025.102003","journal-title":"Biochem Biophys Rep"},{"key":"5302_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.591667","volume":"11","author":"X Hua","year":"2020","unstructured":"Hua X, Ge S, Chen J, Zhang L, Tai S, Liang C (2020) Effects of RNA binding proteins on the prognosis and malignant progression in prostate cancer. Front Genet 11:591667","journal-title":"Front Genet"},{"key":"5302_CR14","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3390\/cancers13112563","volume":"13","author":"M Kanayama","year":"2021","unstructured":"Kanayama M, Lu C, Luo J, Antonarakis ES (2021) AR splicing variants and resistance to AR targeting agents. Cancers 13:2563","journal-title":"Cancers"},{"key":"5302_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-020-00927-w","volume":"13","author":"H Qin","year":"2020","unstructured":"Qin H, Ni H, Liu Y, Yuan Y, Xi T, Li X, Zheng L (2020) RNA-binding proteins in tumor progression. J Hematol Oncol 13:90. https:\/\/doi.org\/10.1186\/s13045-020-00927-w","journal-title":"J Hematol Oncol"},{"key":"5302_CR16","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/onc.2013.284","volume":"33","author":"LL Liu","year":"2014","unstructured":"Liu LL, Xie N, Sun S, Plymate S, Mostaghel E, Dong X (2014) Mechanisms of the androgen receptor splicing in prostate cancer cells. Oncogene 33:3140\u20133150","journal-title":"Oncogene"},{"key":"5302_CR17","doi-asserted-by":"publisher","first-page":"13426","DOI":"10.1038\/srep13426","volume":"5","author":"J Stockley","year":"2015","unstructured":"Stockley J, Markert E, Zhou Y, Robson CN, Elliott DJ, Lindberg J, Leung HY, Rajan P (2015) The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Sci Rep 5:13426","journal-title":"Sci Rep"},{"key":"5302_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.molcel.2016.05.034","volume":"63","author":"BE Aubol","year":"2016","unstructured":"Aubol BE, Wu G, Keshwani MM, Movassat M, Fattet L, Hertel KJ, Fu X-D, Adams JA (2016) Release of SR proteins from CLK1 by SRPK1: a symbiotic kinase system for phosphorylation control of pre-mRNA splicing. Mol Cell 63:218\u2013228","journal-title":"Mol Cell"},{"key":"5302_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2018251118","volume":"118","author":"BE Aubol","year":"2021","unstructured":"Aubol BE, Wozniak JM, Fattet L, Gonzalez DJ, Adams JA (2021) CLK1 reorganizes the splicing factor U1\u201370K for early spliceosomal protein assembly. Proc Natl Acad Sci USA 118:e2018251118. https:\/\/doi.org\/10.1073\/pnas.2018251118","journal-title":"Proc Natl Acad Sci USA"},{"key":"5302_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12935-020-01739-1","volume":"21","author":"D Tong","year":"2021","unstructured":"Tong D (2021) The role of JMJD6\/U2AF65\/AR-V7 axis in castration-resistant prostate cancer progression. Cancer Cell Int 21:45. https:\/\/doi.org\/10.1186\/s12935-020-01739-1","journal-title":"Cancer Cell Int"},{"key":"5302_CR21","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/ijc.30893","volume":"141","author":"B Wang","year":"2017","unstructured":"Wang B, Lo U, Wu K, Kapur P, Liu X, Huang J, Chen W, Hernandez E, Santoyo J, Ma S, Pong R, He D, Cheng Y, Hsieh J (2017) Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer, Intl. J Cancer 141:2121\u20132130. https:\/\/doi.org\/10.1002\/ijc.30893","journal-title":"J Cancer"},{"key":"5302_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12672-014-0177-y","volume":"5","author":"CCT Sprenger","year":"2014","unstructured":"Sprenger CCT, Plymate SR (2014) The link between androgen receptor splice variants and castration-resistant prostate cancer. Horm Canc 5:207\u2013217. https:\/\/doi.org\/10.1007\/s12672-014-0177-y","journal-title":"Horm Canc"},{"key":"5302_CR23","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1158\/0008-5472.CAN-20-1807","volume":"81","author":"A Paschalis","year":"2022","unstructured":"Paschalis A, Welti J, Neeb AJ, Yuan W, Figueiredo I, Pereira R, Ferreira A, Riisnaes R, Rodrigues DN, Jim\u00e9nez-Vacas JM, Kim S, Uo T, Micco PD, Tumber A, Islam MdS, Moesser MA, Abboud M, Kawamura A, Gurel B, Christova R, Gil VS, Buroni L, Crespo M, Miranda S, Lambros MB, Carreira S, Tunariu N, Alimonti A, Al-Lazikani B, Schofield CJ, Plymate SR, Sharp A, de Bono JS (2022) SU2C\/PCF international prostate cancer dream team, JMJD6 Is a druggable oxygenase that regulates AR-V7 expression in prostate cancer. Can Res 81:1087\u20131100. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1807","journal-title":"Can Res"},{"key":"5302_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70096","volume":"8","author":"T Saini","year":"2025","unstructured":"Saini T, Srivastava D, Raut R, Mishra P, Misra A (2025) Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) promotes castration-resistant prostate cancer progression by regulating AR-V7 mRNA stability. Cancer Rep (Hoboken) 8:e70096. https:\/\/doi.org\/10.1002\/cnr2.70096","journal-title":"Cancer Rep (Hoboken)"},{"key":"5302_CR25","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1158\/1535-7163.MCT-17-0030","volume":"16","author":"R Tummala","year":"2017","unstructured":"Tummala R, Lou W, Gao AC, Nadiminty N (2017) Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells. Mol Cancer Ther 16:2770\u20132779","journal-title":"Mol Cancer Ther"},{"key":"5302_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41419-021-03966-4","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang M, Sun Y, Huang C-P, Luo J, Zhang L, Meng J, Liang C, Chang C (2021) Targeting the Lnc-OPHN1-5\/androgen receptor\/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression. Cell Death Dis 12:855","journal-title":"Cell Death Dis"},{"key":"5302_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1101\/gad.235770.113","volume":"28","author":"M Jangi","year":"2014","unstructured":"Jangi M, Boutz PL, Paul P, Sharp PA (2014) Rbfox2 controls autoregulation in RNA-binding protein networks. Genes Dev 28:637\u2013651","journal-title":"Genes Dev"},{"key":"5302_CR28","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.molcel.2015.03.016","volume":"58","author":"A Misra","year":"2015","unstructured":"Misra A, Ou J, Zhu LJ, Green MR (2015) Global promotion of alternative internal exon usage by mRNA 3\u2032 end formation factors. Mol Cell 58:819\u2013831","journal-title":"Mol Cell"},{"key":"5302_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12935-022-02452-x","volume":"22","author":"S Wang","year":"2022","unstructured":"Wang S, Lv W, Li T, Zhang S, Wang H, Li X, Wang L, Ma D, Zang Y, Shen J, Xu Y, Wei W (2022) Dynamic regulation and functions of mRNA m6A modification. Cancer Cell Int 22:48. https:\/\/doi.org\/10.1186\/s12935-022-02452-x","journal-title":"Cancer Cell Int"},{"key":"5302_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/s41420-022-01040-2","volume":"8","author":"H Yan","year":"2022","unstructured":"Yan H, Zhang L, Cui X, Zheng S, Li R (2022) Roles and mechanisms of the m6A reader YTHDC1 in biological processes and diseases. Cell Death Discovery 8:237","journal-title":"Cell Death Discovery"},{"key":"5302_CR31","doi-asserted-by":"publisher","DOI":"10.15252\/embr.202254686","author":"L Chen","year":"2022","unstructured":"Chen L, Fu Y, Hu Z, Deng K, Song Z, Liu S, Li M, Ou X, Wu R, Liu M, Li R, Gao S, Cheng L, Chen S, Xu A (2022) A reader YTHDC1 suppresses proximal alternative polyadenylation sites by interfering with the 3\u2032 processing machinery. EMBO Rep. https:\/\/doi.org\/10.15252\/embr.202254686","journal-title":"EMBO Rep"},{"key":"5302_CR32","unstructured":"M.L. Zuley, R. Jarosz, B.F. Drake, D. Rancilio, A. Klim, K. Rieger-Christ, J. Lemmerman, 2016 The Cancer Genome Atlas Prostate Adenocarcinoma Collection (TCGA-PRAD)(Version 4), Cancer Imaging Arch"},{"key":"5302_CR33","doi-asserted-by":"publisher","first-page":"5507","DOI":"10.1200\/JCO.2020.38.15_suppl.5507","volume":"38","author":"EJ Small","year":"2020","unstructured":"Small EJ, Zhao S, Chen WS, Li H, Foye A, Sj\u00f6str\u00f6m M, Hua JJ, Aggarwal RR, Alumkal JJ, Beer TM, Gleave M, Rettig M, Witte O, Lara P, Chinnaiyan A, Maher C, Quigley DA, Feng FY (2020) The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT). JCO 38:5507\u20135507. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5507","journal-title":"JCO"},{"key":"5302_CR34","unstructured":"M.K. David, S.W. Leslie, Prostate Specific Antigen, in: StatPearls, StatPearls Publishing, Treasure Island (FL), 2024. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557495\/. Accessed 25 Sep 2024."},{"key":"5302_CR35","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1158\/1078-0432.CCR-16-1070","volume":"23","author":"F Qu","year":"2017","unstructured":"Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee G-SM (2017) Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res 23:726\u2013734","journal-title":"Clin Cancer Res"},{"key":"5302_CR36","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1038\/s41388-019-0696-7","volume":"38","author":"MV Luna Velez","year":"2019","unstructured":"Luna Velez MV, Verhaegh GW, Smit F, Sedelaar JM, Schalken JA (2019) Suppression of prostate tumor cell survival by antisense oligonucleotide-mediated inhibition of AR-V7 mRNA synthesis. Oncogene 38:3696\u20133709","journal-title":"Oncogene"},{"key":"5302_CR37","doi-asserted-by":"publisher","first-page":"40957","DOI":"10.1038\/srep40957","volume":"7","author":"D Jones","year":"2017","unstructured":"Jones D, Noble M, Wedge SR, Robson CN, Gaughan L (2017) Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. Sci Rep 7:40957","journal-title":"Sci Rep"},{"key":"5302_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100915","volume":"14","author":"M Sugiura","year":"2021","unstructured":"Sugiura M, Sato H, Okabe A, Fukuyo M, Mano Y, Shinohara K, Rahmutulla B, Higuchi K, Maimaiti M, Kanesaka M (2021) Identification of AR-V7 downstream genes commonly targeted by AR\/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Transl Oncol 14:100915","journal-title":"Transl Oncol"},{"key":"5302_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s10555-021-10006-2","volume":"40","author":"A Sebesty\u00e9n","year":"2021","unstructured":"Sebesty\u00e9n A, Dank\u00f3 T, Sztankovics D, Moldvai D, Raffay R, Cervi C, Krencz I, Zsiros V, Jeney A, Pet\u0151v\u00e1ri G (2021) The role of metabolic ecosystem in cancer progression \u2014 metabolic plasticity and mTOR hyperactivity in tumor tissues. Cancer Metastasis Rev 40:989\u20131033. https:\/\/doi.org\/10.1007\/s10555-021-10006-2","journal-title":"Cancer Metastasis Rev"},{"key":"5302_CR40","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1158\/1541-7786.MCR-14-0131","volume":"12","author":"S Das","year":"2014","unstructured":"Das S, Krainer AR (2014) Emerging functions of SRSF1, splicing factor and oncoprotein, RNA metabolism and cancer. Mol Cancer Res 12:1195\u20131204","journal-title":"Mol Cancer Res"},{"key":"5302_CR41","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1016\/j.celrep.2017.11.091","volume":"21","author":"L Chen","year":"2017","unstructured":"Chen L, Luo C, Shen L, Liu Y, Wang Q, Zhang C, Guo R, Zhang Y, Xie Z, Wei N (2017) SRSF1 prevents DNA damage and promotes tumorigenesis through regulation of DBF4B pre-mRNA splicing. Cell Rep 21:3406\u20133413","journal-title":"Cell Rep"},{"key":"5302_CR42","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s10120-020-01062-8","volume":"23","author":"N Babu","year":"2020","unstructured":"Babu N, Pinto SM, Biswas M, Subbannayya T, Rajappa M, Mohan SV, Advani J, Rajagopalan P, Sathe G, Syed N, Radhakrishna VD, Muthusamy O, Navani S, Kumar RV, Gopisetty G, Rajkumar T, Radhakrishnan P, Thiyagarajan S, Pandey A, Gowda H, Majumder P, Chatterjee A (2020) Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer. Gastric Cancer 23:796\u2013810. https:\/\/doi.org\/10.1007\/s10120-020-01062-8","journal-title":"Gastric Cancer"},{"key":"5302_CR43","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13045-021-01072-8","volume":"14","author":"S Chen","year":"2021","unstructured":"Chen S, Yang C, Wang Z-W, Hu J-F, Pan J-J, Liao C-Y, Zhang J-Q, Chen J-Z, Huang Y, Huang L, Zhan Q, Tian Y-F, Shen B-Y, Wang Y-D (2021) CLK1\/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. J Hematol Oncol 14:60. https:\/\/doi.org\/10.1186\/s13045-021-01072-8","journal-title":"J Hematol Oncol"},{"key":"5302_CR44","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12967-021-02954-8","volume":"19","author":"J-Q Huang","year":"2021","unstructured":"Huang J-Q, Li H-F, Zhu J, Song J-W, Zhang X-B, Gong P, Liu Q-Y, Zhou C-H, Wang L, Gong L-Y (2021) SRPK1\/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-\u03baB activation in colon cancer. J Transl Med 19:280. https:\/\/doi.org\/10.1186\/s12967-021-02954-8","journal-title":"J Transl Med"},{"key":"5302_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cells9010019","volume":"9","author":"IP Nikas","year":"2019","unstructured":"Nikas IP, Themistocleous SC, Paschou SA, Tsamis KI, Ryu HS (2019) Serine-arginine protein kinase 1 (SRPK1) as a prognostic factor and potential therapeutic target in cancer: current evidence and future perspectives. Cells 9:19","journal-title":"Cells"},{"key":"5302_CR46","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/cells9122648","volume":"9","author":"FI Montalto","year":"2020","unstructured":"Montalto FI, De Amicis F (2020) Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma. Cells 9:2648","journal-title":"Cells"},{"key":"5302_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12929-016-0288-6","volume":"23","author":"Y-A Zhang","year":"2016","unstructured":"Zhang Y-A, Liu H-N, Zhu J-M, Zhang D-Y, Shen X-Z, Liu T-T (2016) RNA binding protein Nova1 promotes tumor growth in vivo and its potential mechanism as an oncogene may due to its interaction with GABAA Receptor-\u03b32. J Biomed Sci 23:71. https:\/\/doi.org\/10.1186\/s12929-016-0288-6","journal-title":"J Biomed Sci"},{"key":"5302_CR48","doi-asserted-by":"publisher","first-page":"8102","DOI":"10.3390\/ijms24098102","volume":"24","author":"A Di Matteo","year":"2023","unstructured":"Di Matteo A, Belloni E, Pradella D, Chiaravalli AM, Pini GM, Bugatti M, Alfieri R, Barzan C, Franganillo Tena E, Bione S (2023) Alternative splicing changes promoted by NOVA2 upregulation in endothelial cells and relevance for gastric cancer. Int J Mol Sci 24:8102","journal-title":"Int J Mol Sci"},{"key":"5302_CR49","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM (2013) VEGF targets the tumour cell. Nat Rev Cancer 13:871\u2013882","journal-title":"Nat Rev Cancer"},{"key":"5302_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41419-019-1407-6","volume":"10","author":"CF Warren","year":"2019","unstructured":"Warren CF, Wong-Brown MW, Bowden NA (2019) BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis 10:177","journal-title":"Cell Death Dis"},{"key":"5302_CR51","first-page":"2838","volume":"138","author":"Y Sheng","year":"2021","unstructured":"Sheng Y, Wei J, Yu F, Xu H, Yu C, Wu Q, Liu Y, Li L, Cui X, Gu X (2021) A critical role of nuclear m6A reader YTHDC1 in leukemogenesis by regulating MCM complex\u2013mediated DNA replication, Blood, The Journal of the American Society of. Hematology 138:2838\u20132852","journal-title":"Hematology"},{"key":"5302_CR52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.gene.2018.05.095","volume":"670","author":"S Uzor","year":"2018","unstructured":"Uzor S, Zorzou P, Bowler E, Porazinski S, Wilson I, Ladomery M (2018) Autoregulation of the human splice factor kinase CLK1 through exon skipping and intron retention. Gene 670:46\u201354","journal-title":"Gene"},{"key":"5302_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2024.114026","volume":"438","author":"T Saini","year":"2024","unstructured":"Saini T, Gupta P, Raut R, Nayak V, Bharathnaveen P, Mishra P, Misra A (2024) AR-V7 expression facilitates accelerated G2\/M phase transition in castration-resistant prostate cancer. Exp Cell Res 438:114026","journal-title":"Exp Cell Res"},{"key":"5302_CR54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.molcel.2016.01.012","volume":"61","author":"W Xiao","year":"2016","unstructured":"Xiao W, Adhikari S, Dahal U, Chen Y-S, Hao Y-J, Sun B-F, Sun H-Y, Li A, Ping X-L, Lai W-Y (2016) Nuclear m6A reader YTHDC1 regulates mRNA splicing. Mol Cell 61:507\u2013519","journal-title":"Mol Cell"},{"key":"5302_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111784","volume":"41","author":"K Timcheva","year":"2022","unstructured":"Timcheva K, Dufour S, Touat-Todeschini L, Burnard C, Carpentier MC, Chuffart F, Merret R, Helsmoortel M, Ferr\u00e9 S, Gr\u00e9zy A, Cout\u00e9 Y, Rousseaux S, Khochbin S, Vourc\u2019h C, Bousquet-Antonelli C, Kiernan R, Seigneurin-Berny D, Verdel A (2022) Chromatin-associated YTHDC1 coordinates heat-induced reprogramming of gene expression. Cell Rep 41:111784. https:\/\/doi.org\/10.1016\/j.celrep.2022.111784","journal-title":"Cell Rep"},{"key":"5302_CR56","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021107640","volume":"41","author":"AM Jobbins","year":"2022","unstructured":"Jobbins AM, Campagne S, Weinmeister R, Lucas CM, Gosliga AR, Clery A, Chen L, Eperon LP, Hodson MJ, Hudson AJ, Allain FH (2022) Exon-independent recruitment of SRSF1 is mediated by U1 snRNP stem-loop 3. EMBO J 41:e107640","journal-title":"EMBO J"},{"key":"5302_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05544-8","author":"S Yuan","year":"2023","unstructured":"Yuan S, He SH, Li LY, Xi S, Weng H, Zhang JH, Wang DQ, Guo MM, Zhang H, Wang SY, Ming DJ, Liu MY, Hu H, Zeng XT (2023) A potassium-chloride co-transporter promotes tumor progression and castration resistance of prostate cancer through m6A reader YTHDC1. Cell Death and Dissease. https:\/\/doi.org\/10.1038\/s41419-022-05544-8","journal-title":"Cell Death and Dissease"},{"key":"5302_CR58","unstructured":"Frompolyadenylation to splicing: Dual role for mRNA 3\u2019 end formation factors"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05302-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-025-05302-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-025-05302-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:47:33Z","timestamp":1758970053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-025-05302-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5302"],"URL":"https:\/\/doi.org\/10.1007\/s11010-025-05302-2","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}